Skip to main content
Clinical Trials/NCT03621488
NCT03621488
Recruiting
Not Applicable

Randomized Controlled Study of the Efficacy of Behavioral Self-Activation Through Virtual Reality in the Treatment of Depression

University Hospital, Montpellier1 site in 1 country80 target enrollmentNovember 29, 2019
ConditionsDepression

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Depression
Sponsor
University Hospital, Montpellier
Enrollment
80
Locations
1
Primary Endpoint
Evolution of depression
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

Depression is a major handicap in daily life and is often treated by behavioral activation (CA), including the Brief Behavioral Activation Treatment for Depression (BATD).The CA principle is to set up activities, in keeping with the values of the individual. Other tools associated with the CA deserve to be explored as virtual reality (VR), which offers scenarios and sensations similar to real life and a sense of life. in a safe and controlled environment, with the support of the therapist.The main objective is to compare the effectiveness of the program "BATD with RV" versus "BATD without RV" on the intensity of the depressive symptomatology and CA in everyday life.

Methodology: This is a randomized, blinded study. Inclusion criteria are: 18 to 70 years old; unipolar depression diagnosis; Showing a score of ≥ 17 on the BDI-II. 80 subjects will be recruited over 24 months and randomized into 2 groups: 1) intervention group program BATD in VR; 2) BATD program intervention group without RV, lasting 45 minutes.

Judgment Criteria: The effectiveness of the intervention will be evaluated by the BDI-II scale and the Behavioral Activation for Depression Scale (BADS).

Outcomes: A new management of depression (AC with RV) to improve the quality of life of the patient; proof of its effectiveness; a generalization of this care; and recognition of its effectiveness in the scientific community.

Registry
clinicaltrials.gov
Start Date
November 29, 2019
End Date
June 7, 2026
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Adults aged 18 to 70,
  • Having a diagnosis of unipolar depressive disorder characterized (diagnostic criteria of depression of DSM-V),
  • Primary depression and not secondary to another disorder (eg social phobia, OCD, severe personality disorder, ASD, TCA, ect.)
  • Showing a score greater than or equal to 17 points on the IDB-II,
  • Followed by a psychiatrist from the University Hospital of Montpellier or a liberal,
  • Can read, understand and speak French,
  • To be affiliated or beneficiary of a social security scheme.
  • Collection of informed consent.

Exclusion Criteria

  • (1) History of head trauma or recent central neurological conditions only (2) Current treatment by seismotherapy or rTMS or CBT. (3) Exclusion from all substance-related disorders except tobacco-related disorder (DSM-V)

Outcomes

Primary Outcomes

Evolution of depression

Time Frame: 0 and 6 months

Beck Depression Inventory version II (BDI-II; depression) ; decrease BDI-II score between 0 and 6 months.

Secondary Outcomes

  • Evolution of depression(0 and 3 months)
  • Life quality(3 and 6 months)
  • Therapeutic alliance(0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 weeks; 13 and 6 months)
  • Number of activities(3 and 6 months)
  • Evolution of depressive symptoms(0, 3 and 6 months)
  • Hopelessness(3 and 6 months)
  • Physical fatigue(3 and 6 months)

Study Sites (1)

Loading locations...

Similar Trials